Celebrating the great minds that bring us innovation in small molecules, biopharmaceuticals, and advanced medicine.
How is African pharma coping with the COVID-19 pandemic?
A vaccine must be able to reach patients who need it. Reliable partners and procedures are a must.
Global access to the vaccine is essential to provide protection against the virus. A big hurdle to accessibility will likely be price.
Most clinical trials against COVID-19 exclude the very patients most at risk from the disease.
A typical vaccine takes around 10 to 12 years to reach the market. A key question: “Where should we base production?”
We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis.
We speak with Laertis Ikonomou and Dan Weiss about the ISCT's work to combat unproven cell therapies.
Queenie Jang reveals how the ISCT created an interactive virtual conference in under two months.
Virus-based vaccines were the first foray into immunization, but the field has had to move on and embrace new approaches.
How do we manage the fallout caused by the COVID-19 pandemic?
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.